Health Care • Biotechnology: Pharmaceutical Preparations
$11.31 ▲ +0.38
(+3.43%)
MKT CAP: $277.0M • VOL: 149.2K
52W L $7 52W H $45
ROARABLE / RQD
D- • 38/100
PIOTROSKI
3 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$10
MEDIAN
$13
MEAN
$13
HIGH
$15
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE LYEL TAPE
LYEL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $13.69 | $13.01 | 2025-02-14 | $10.29 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $14.25 | $13.35 | 2025-02-06 | $10.63 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $12.89 | $12.44 | 2025-01-29 | $10.86 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $11.54 | — | 2025-01-17 | $11.08 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $9.95 | $10.74 | 2025-01-09 | $10.07 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $13.46 | $11.76 | 2024-12-18 | $9.84 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $10.97 | $11.42 | 2024-12-04 | $10.52 | -4.3% | 48% | C |